Omitting completion axillary lymph node dissection in breast cancer patients with sentinel lymph node micrometastases undergoing mastectomy : results from the prospective SENOMIC trial
Background Breast cancer patients undergoing mastectomy are not well represented in studies evaluating the omission of completion axillary lymph node dissection (cALND) due to sentinel lymph node (SLN) metastases. Methods The prospective multicentre SENOMIC cohort trial included patients with breast cancer and SLN micrometastases between October 2013 and December 2022. Completion ALND was omitted
